Determining accurate costs for genomic sequencing technologies-a necessary prerequisite

Jathishinie Jegathisawaran; Kate Tsiplova; Robin Hayeems; Wendy J Ungar

doi:10.1007/s12687-019-00442-7

Determining accurate costs for genomic sequencing technologies-a necessary prerequisite

J Community Genet. 2020 Apr;11(2):235-238. doi: 10.1007/s12687-019-00442-7. Epub 2019 Nov 15.

Authors

Jathishinie Jegathisawaran¹, Kate Tsiplova¹, Robin Hayeems^{1

2}, Wendy J Ungar^{3

4}

Affiliations

¹ Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 11th floor, 686 Bay Street, Toronto, Ontario, M5G 0A4, Canada.
² Institute of Health Policy, Management and Evaluation, University of Toronto, 4th floor, 155 College Street, Toronto, Ontario, M5T 3M6, Canada.
³ Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 11th floor, 686 Bay Street, Toronto, Ontario, M5G 0A4, Canada. wendy.ungar@sickkids.ca.
⁴ Institute of Health Policy, Management and Evaluation, University of Toronto, 4th floor, 155 College Street, Toronto, Ontario, M5T 3M6, Canada. wendy.ungar@sickkids.ca.

Abstract

Genome sequencing (GS) is increasingly being translated into clinical practice and is a technology characterized by a complex multi-step workflow. Funding decisions for GS would be aided by formal economic evaluation of GS platforms, but these analyses require detailed costing. This article addresses the importance of and challenges associated with costing GS using a GS microcosting project in autism spectrum disorder as an illustrative example.

Keywords: Autism spectrum disorder; Chromosomal microarray; Economic evaluation; Genome sequencing; Health technology assessment; Microcosting.

Abstract

Grants and funding